UPDATE 2-Celgene shares fall on disappointing data, results | Reuters
Links shared publicly online about this topic.
- 590total visits
UPDATE 2-Celgene shares fall on disappointing data, results | Reuters
* Abraxane fails to significantly extend lung cancer PFS * Non-GAAP EPS 73 cents vs Street view 75 cents * Q4 Revlimid sales up 42 pct to $708 million * Sees 2011 non-GAAP EPS of $3.30 to $3.35
View full resource at reuters.com
Tags: Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Lung
Most Recently Shared on January 11, 2011 at 3:54 am By:
Non-small cell #LungCancer trial with Abraxane negative for overall survival benefit: http://reut.rs/AbxneNSCLC
Advertisement
